35 results
Thumbnail

D2.216 - Effectiveness and safety of subcutaneous immunotherapy with Depigmented-Polymerized Cat Extract: real-world clinical evidence

Thumbnail

D2.217 - Structured Follow-Up Intervals Enhance Adherence to Sublingual Immunotherapy in Patients with Allergic Rhinitis: Real-World Evidence from a Stepwise Approach

Thumbnail

D2.218 - Effectiveness of the 300IR house dust mite sublingual tablet according to the patients’ sensitisation and allergy profile in the real-world, non-interventional VORAN study

Thumbnail

D2.219 - Effectiveness of the 300IR house dust mite sublingual tablet in the real-world, non-interventional VORAN study: a responder analysis

Thumbnail

D2.222 - A real-world observational study following the first year of SQ grass or SQ tree SLIT-tablet treatment to evaluate persistence and adherence in routine clinical practice among general practitioners in Norway

Thumbnail

D2.225 - Characterizing skin-resident antigen presenting cell responses to plant-based Fel d 1 Bioparticles

Thumbnail

D2.226 - Evaluation of the Immunogenicity and Stability of an Aluminum-Adsorbed Allergen Immunotherapy Using Specific IgG Titration in a Murine Model

Thumbnail

D2.228 - Effectiveness and Safety of Subcutaneous Immunotherapy for Patients Allergic to Either Cat Dander or Dermatophagoides/Cat Dander: Real World Data

Thumbnail

D2.214 - TAPAS – non-inferiority of clinical effectiveness in children compared to adults: 3-year interim results of a long-term NIS

Thumbnail

D2.215 - A Prospective Long-Term Cohort Study with Seasonal Allergic Rhinitis (TAPAS) with MATAs in tree- and grass-allergic patients

Thumbnail

D2.220 - US Regional Difference in Allergen Immunotherapy Prescription Patterns: Focus on the South

Thumbnail

D2.221 - Exploring the effect of HDM SLIT-tablets on atopic dermatitis prescriptions in patients with pre-existing atopic dermatitis: Results from the Real-world Evidence of house dust Mite Immunotherapy Tablets (REMIT) study

Thumbnail

D2.223 - Using IgG antibodies to measure product potency for modified allergoid AIT

Thumbnail

D2.227 - US Regional Difference in Allergen Immunotherapy Prescription Patterns: Focus on Puerto Rico

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study